phentolamine has been researched along with Hypogonadism in 1 studies
Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.
phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.
Hypogonadism: Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santen, RJ | 1 |
| Bardin, CW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reproductive Hormonal Alterations in Obesity, AIMS #1 & #2[NCT01457703] | 62 participants (Actual) | Interventional | 2010-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Follicle-stimulating hormone was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups. (NCT01457703)
Timeframe: Measured hourly and averaged over the 12 hour study visit
| Intervention | IU/L (Mean) |
|---|---|
| BMI ≥30 kg/m2 | 3.8 |
| BMI 18-25 kg/m2 | 3.3 |
Follicle-stimulating hormone was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups. (NCT01457703)
Timeframe: Measured hourly and averaged over the 12 hour study visit
| Intervention | IU/L (Mean) |
|---|---|
| BMI ≥30 kg/m2 | 5.31 |
| BMI 18-25 kg/m2 | 6.18 |
Luteinizing Hormone (LH) Pulse Amplitude was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups. (NCT01457703)
Timeframe: Measured hourly and averaged over the 12 hour study visit
| Intervention | IU/L (Mean) |
|---|---|
| BMI ≥30 kg/m2 | 4.1 |
| BMI 18-25 kg/m2 | 3.6 |
Luteinizing Hormone (LH) Pulse Amplitude was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups. (NCT01457703)
Timeframe: Measured hourly and averaged over the 12 hour study visit
| Intervention | IU/L (Mean) |
|---|---|
| BMI ≥30 kg/m2 | 2.21 |
| BMI 18-25 kg/m2 | 4.44 |
Pregnanediol glucuronide (PdG) was collected daily over the course of one menstrual cycle and averaged. (NCT01457703)
Timeframe: Averaged over the length of menstrual cycle
| Intervention | ug/cycle (Mean) |
|---|---|
| BMI ≥30 kg/m2 | 54.1 |
| BMI 18-25 kg/m2 | 88.7 |
1 other study available for phentolamine and Hypogonadism
| Article | Year |
|---|---|
Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiologic mechanisms.
Topics: Adult; Amenorrhea; Anorexia Nervosa; Chlorpromazine; Female; Follicle Stimulating Hormone; Half-Life | 1973 |